Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen
When developing breakthrough therapies, distinguish between creating a "good drug" versus a "good product." A good drug helps individual patients in controlled settings. A good product integrates into existing healthcare infrastructure so it can reach populations at scale. The difference determines
2h 6mKey Takeaway
When developing breakthrough therapies, distinguish between creating a "good drug" versus a "good product." A good drug helps individual patients in controlled settings. A good product integrates into existing healthcare infrastructure so it can reach populations at scale. The difference determines whether your innovation saves dozens or millions of lives. Design solutions that work within current systems—oncology infusion clinics, IV administration, standard procedures—then iterate from there.
Episode Overview
Jacob Glanville, CEO of Strand Therapeutics, discusses his company's groundbreaking approach to genetic medicine, particularly their success in treating late-stage melanoma by reprogramming cancer cells to signal the immune system. He emphasizes the critical difference between creating effective drugs and building scalable products that integrate into existing healthcare infrastructure, while outlining how China's clinical trial advantage threatens American biotech leadership.
Key Insights
The Product vs. Drug Distinction in Medicine
A "good drug" can help individual patients in specific conditions, but a "good product" can be delivered safely and effectively at scale through existing infrastructure. For example, CAR-T cell therapies are phenomenal drugs that cure certain blood cancers, but they cost $750,000 to manufacture, take three months to produce, and require removing cells from patients. This makes them bad products because they can't impact population-level health despite their individual efficacy.
The Genetic Medicine Delivery Paradox
The biotech industry has spent 30 years mastering genetic medicine delivery to the liver (step one) but hasn't solved delivery to other organs (step two). Everyone claims "delivery" is the problem, but Glanville argues it's actually three problems disguised as one: potency, specificity, and delivery. Solving this three-part challenge is the key to unlocking genetic medicine's potential across all disease areas.
The Abscopal Response Breakthrough
Strand demonstrated something rarely seen in oncology: injecting their genetic medicine into accessible tumors activated the immune system so effectively that it attacked distant, untreated tumors throughout the body—including visceral metastases in organs. This "abscopal response" means patients don't die from skin lesions being treated; the therapy addresses the organ metastases that actually kill melanoma patients. Two of their first three patients from summer 2024 were still on the trial 18 months later.
China's Clinical Trial Infrastructure Advantage
China has built an industrialized first-in-human clinical trial infrastructure that is faster and cheaper than America's system. What started as a place for American companies to run early trials has created a flywheel where Chinese companies now run trials faster than US companies, discover drugs in China, then bring them to the United States. This shift in efficiency is redirecting risk capital away from American biotech.
Infrastructure as the Rate-Limiting Step in Medical Innovation
AI-designed proteins, human-designed therapies, and high-throughput screening can all create breakthrough treatments. The constraint isn't discovery—it's the medical biomedicine infrastructure to safely deliver these innovations to patients at scale. Medicine is moving toward smaller, more refined indications, but we'll reach technological capability for bespoke treatments much faster than we'll build the infrastructure to deliver them effectively.
Notable Quotes
"One of the greatest accomplishments in that career that I've had thus far is being able to say that you did help a person. If that was just one person, one patient, I'd say, 'Wow, what a career.' We dream of more. We have big ambitions here at Strand."
"When we look at these steps, these are lives. The lines that go down on this, the vertical part of the step is someone's loved one dying. But the ones that go horizontal and every time you see something go further along that is someone who got to experience even if it's just three months you have no idea what that means within that person's life."
"There's a difference between a good drug and a good product. The good drug is can someone take this and it does something. A good product is much more where the idea of how we get medicines to people come into play."
"In biotech, in genetic medicine, the joke is like step one prove it works in the liver, step two question mark, step three we'll treat all these diseases. And after 30 years we've really nailed step one. And step two has remained this big question mark."
"What we don't have is the infrastructure, the medical biomedicine infrastructure that gets any of these things, these discoveries, whether they're made by a human with Microsoft Word stitching amino acids together, whether they're made by an LLM that knows exactly all the pieces—it doesn't matter. What matters is how we're going to get those into patients."
Action Items
-
1
Design for Existing Infrastructure First
When building breakthrough solutions, design them to integrate with existing systems and workflows before trying to revolutionize the entire industry. In healthcare, this means creating therapies that work with standard infusion clinics and IV administration rather than requiring entirely new treatment paradigms. You'll have far greater near-term impact by plugging into what already exists.
-
2
Apply First Principles Thinking to Complex Problems
When everyone gives you a simple answer to a complex problem (like 'it's a delivery issue'), break it down to fundamental components. Ask: what are the actual constraints? Often what appears to be one problem is actually multiple challenges disguised as one. Identify each component separately, then solve them systematically.
-
3
Focus on Population-Level Impact, Not Just Individual Wins
Evaluate your solutions not just by whether they work for one person, but whether they can scale to help thousands or millions. Consider cost of goods, time to delivery, ease of administration, and accessibility across different healthcare settings including rural communities. A therapy that works brilliantly but costs $750,000 and takes three months won't change population-level health outcomes.
-
4
Build Modular Solutions That Enable Rapid Iteration
Create foundational infrastructure that allows you to swap components quickly. Once Strand proves their IV delivery system works for tumors, they can design new therapeutic proteins in six weeks and deploy them using the same proven delivery mechanism. Build systems where you establish safety and efficacy once, then iterate on the payload or specific application.